Ultragenyx Doses First Patient in Aurora Study for Angelman Syndrome Treatment

Ultragenyx Pharmaceutical has dosed the first patient in the Aurora study evaluating GTX-102 for Angelman syndrome. The study will expand the treatment population to include younger and older patients, and those with other non-deletion genotypes not included in the Phase 3 Aspire study. The Aurora study will enroll approximately 60 participants across all genotypes, with some additional countries or regions included.